rais tp enhanc clariti
guidanc call ep vs consensu
ahead consensu midpoint predic revenu
rang billion also ahead plan vs
notabl expect compris revenu
repres run rate million annual
contribut top client encourag dynam
diversifi custom base also reiter guidanc
vs consensu maintain ep
rais ep better
revenu trajectori share repurchas partial off-set modestli
lower margin profil greater clariti near term prospect
boost target price risk includ shift
reiter outperform encourag iclr rel clean
constant currenc revenu growth
importantli revenu growth exclud underappreci
dynam view continu improv custom mix
gener expect rise yoy share repurchas
activ remain focu like target tuck-in acquisit nearbi
commerci offer recent mapi
acquisit global data asset howev would note larger
transact necessarili tabl given potenti interest
sizeabl opportun cours
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
icon public limit compani icon ireland-bas contract
servic pharmaceut biotechnolog medic devic
price jan rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat iclr assum substanti
new busi win addit project award offset
sizabl cancel increment profit margin expans
pronounc strength spend outsourc demand
grey sky valuat iclr assum greater-
than-expect declin busi largest custom
consolid capit deploy misstep weaken demand
outsourc
compani mention price
